Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Oncothyreon said it does not plan to move forward with development of PX-866 for GBM after data from 33 evaluable patients with GBM at
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury